Clinical Trials Logo

Proteus Syndrome clinical trials

View clinical trials related to Proteus Syndrome.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04980872 Active, not recruiting - Clinical trials for PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

Start date: November 2, 2021
Phase: Phase 2
Study type: Interventional

This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related overgrowth spectrum (PROS) or Proteus Syndrome (PS). This is an extension of other miransertib studies (MK-7075-002 [NCT03094832] or ArQule CU/EAP [NCT03317366]), and may also enroll participants who are approved for MK-7075-002 but have not yet started miransertib therapy.